The two-day FDA Pharmacy Compounding Advisory Committee (PCAC) session closed Friday July 24, 2026 with 6 of 7 research peptides recommended for the Section 503A Bulks List. Day 1 wins: BPC-157 (8-6-1), KPV (8-6-1), TB-500 (8-6), MOTS-c (7-5-2). Day 2 wins: Semax (8-5), Epitalon (7-4). Day 2 rejection: Emideltide/DSIP. Every one of the 6 wins overrode the FDA career-staff briefing documents that recommended against adding any of the seven peptides. STAT News, Time Magazine, NPR, ABC News, Bloomberg, US News, The Hill, and Washington Times converged on the framing that HHS Secretary Robert F. Kennedy Jr.'s peptide-access push cleared a substantive advisory threshold. Panel composition itself was a substantive factor: eight new PCAC members were named June 29, with at least seven documented to have peptide-industry ties per STAT News. What still has to happen before actual compounding-pharmacy access changes: FDA leadership must review each vote, decide whether to accept it, publish a proposed rule in the Federal Register, run a 60-90 day public comment period, respond to comments, and publish a final rule with an effective date. Rulemaking typically takes 6-18 months per substance from the date the FDA decides to act.
The FDA Pharmacy Compounding Advisory Committee (PCAC) voted 8-6 with 1 abstention on Thursday July 23, 2026 to recommend adding BPC-157 to the Section 503A Bulk Drug Substances List, in a win for HHS Secretary Robert F. Kennedy Jr.'s peptide deregulation agenda. The narrow vote overrode FDA career-staff briefing documents released June 29-30 that recommended against adding any of the seven peptides under review, citing immunogenicity concerns, heavy-metal and microbial contamination in samples pulled from the compounding channel, mislabeled contents, and thin 503A historical use. The vote sequencing during the Thursday session followed extensive public comment; Hims Chief Medical Officer Dr. Anant Vinjamoori argued during his testimony that a no vote would push peptides deeper into an unregulated gray market rather than end the underlying demand. PCAC recommendations are advisory and non-binding; the FDA typically follows them, and formal rulemaking to implement the recommendation would take approximately 6 to 18 months. Panel composition is a significant contextual factor: before the meeting, more than a half-dozen new members with documented ties to the peptide industry were added to the PCAC.
The FDA Pharmacy Compounding Advisory Committee (PCAC) reconvenes Friday July 24, 2026 at 8:00 AM ET at FDA's White Oak Campus in Silver Spring, Maryland for Day 2 of the peptide review. Friday's schedule covers three peptides: DSIP/Emideltide (delta sleep-inducing peptide, a nonapeptide first isolated from rabbit brain in 1974 and nominated for sleep disorders and opioid withdrawal); Semax (a synthetic heptapeptide derived from the ACTH(4-10) sequence developed in Russia as a nootropic and nominated for cerebral ischemia, migraine, and trigeminal neuralgia); and Epitalon (a synthetic tetrapeptide nominated for insomnia and anti-aging applications). FDA career-staff briefing documents recommend against adding any of the three peptides to the Section 503A Bulks List. Panel composition (with at least seven of eight new members carrying peptide-industry ties per STAT News reporting) and Thursday's 8-6 BPC-157 and KPV votes suggest similar narrow majorities may recommend the Day-2 substances against career-staff positions. The Friday session closes at 3:50 PM ET. FDA rulemaking to implement any advisory recommendation would take approximately 6-18 months.
The FDA Pharmacy Compounding Advisory Committee (PCAC) written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET on Wednesday July 22, 2026. Approximately 1,860 public comments have been filed on the seven-peptide review, spanning docket comments from institutional commenters supporting inclusion (Hims & Hers Health among them) and opposing inclusion (PhRMA, Partnership for Safe Medicines, American Pharmacists Association, Public Citizen, Institute for Safe Medication Practices, UC Davis's Paul Knoepfler). Hims Chief Medical Officer Dr. Anant Vinjamoori confirmed Hims will testify at Thursday's July 23 hearing at FDA's White Oak Campus in Silver Spring, Maryland. In pre-hearing remarks, Dr. Vinjamoori said medical providers should be honest about 'the relatively sparse clinical evidence for these peptides' but noted that Hims plans to offer the peptides if the FDA reclassifies them. He also cited nearly a decade of accumulated experience across 'thousands of physicians, close to millions of patients' that in his view supports the peptides' health benefits. FDA career-staff briefing documents recommend against adding any of the seven peptides to the 503A Bulks List. PCAC recommendations are advisory; FDA rulemaking (typically 6-18 months) is required before compounding pharmacies can act on any positive committee recommendation.
The FDA Pharmacy Compounding Advisory Committee (PCAC) peptide meeting is three days out. Written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET on Wednesday July 22, 2026; the two-day meeting opens Thursday July 23 and closes Friday July 24 at FDA's White Oak Campus in Silver Spring, Maryland. Day 1 (Thursday) reviews BPC-157, KPV, TB-500, and MOTS-c for 503A bulks-list eligibility. Day 2 (Friday) reviews DSIP (Emideltide), Semax, and Epitalon. The FDA career-staff briefing documents released June 29-30 recommended against adding any of the seven peptides to the 503A Bulks List, citing immunogenicity concerns, heavy-metal and microbial contamination in compounding-channel samples, mislabeled contents, and thin 503A historical use. The panel composition itself includes at least seven of eight new members named June 29 with documented ties to peptide-related businesses (per STAT News reporting). The written-comment docket has attracted filings from compounding-pharmacy industry groups (Alliance for Pharmacy Compounding, National Community Pharmacists Association, Outsourcing Facilities Association), consumer-safety voices (Public Citizen, Institute for Safe Medication Practices, Partnership for Safe Medicines), and academic scientists (UC Davis's Paul Knoepfler). A 'no' vote does not re-ban anything (the seven peptides came off Category 2 April 23), but a 'yes' vote requires FDA rulemaking (typically 6-18 months) before compounding pharmacies can act on it.
The FDA Pharmacy Compounding Advisory Committee (PCAC) peptide meeting sits four days away, with the written-comment docket FDA-2025-N-6895 closing at 11:59 PM ET on Wednesday July 22, 2026. The two-day meeting opens Thursday July 23 and closes Friday July 24 at FDA's White Oak Campus in Silver Spring, Maryland. Day 1 (Thursday) reviews BPC-157, KPV, TB-500, and MOTS-c for 503A bulks-list eligibility. Day 2 (Friday) reviews DSIP (Emideltide), Semax, and Epitalon. FDA career-staff briefing documents released June 29-30 recommended against adding any of the seven peptides to the 503A Bulks List, citing immunogenicity concerns, heavy-metal and microbial contamination in compounding-channel samples, mislabeled contents, and thin 503A historical use. The written-comment docket has attracted filings from compounding-pharmacy industry groups (Alliance for Pharmacy Compounding, National Community Pharmacists Association, Outsourcing Facilities Association), consumer-safety voices (Public Citizen, Institute for Safe Medication Practices, Partnership for Safe Medicines), academic researchers (UC Davis's Paul Knoepfler), and individual physicians and patients across both sides. A 'no' vote does not re-ban anything (the seven peptides came off Category 2 April 23), but a 'yes' vote requires FDA rulemaking (typically 6-18 months) before compounding pharmacies can act on it.